TGFB1 and systemic sclerosis: In fibrotic disease research, this drug significantly reduced the expression of TGF-β-regulated genes (SERPINE1, CTGF) and decreased dermal myofibroblast infiltration in patients with systemic sclerosis (Rice et al., 2015).